CytoSorbents Corporation (CTSO): Biocon's Annual review and Annual report...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	12
Posts	421
Boards Moderated	0
Alias Born	09/29/2010

ping_pow_princess

Re: None

Tuesday, 07/22/2014 9:55:41 AM

Tuesday, July 22, 2014 9:55:41 AM

Biocon's Annual review and Annual report

Did a find for "cytosorb" and also "sepsis".

Review:
http://www.biocon.com/docs/Annual_Review_2014.pdf

Report:
http://www.biocon.com/docs/Biocon_Annual_Report_2014.pdf

"Cytosorb: Cytosorb is an extracorporeal cytokine filter, in-licensed from Cytosorbents Inc, used in organ transplant and sepsis treatment settings. This product supplements our offerings in the Nephrology and Critical Care divisions, and has seen good traction due to its world class safety profile."

"A novel therapy for sepsis management
– first time in India
A safe and effective extracorporeal
cytokine filter, designed to target the
prevention or treatment of organ failure
Several critically ill patients benefited
from this novel therapy
Excellent Key Opinion Leader (KOL)
uptake driven by patient successes in
cases of severe sepsis"